UCB, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.ucb-usa.com
Clinical Trials
0
Active:0
Completed:0
Trial Phases
0 Phases
Drug Approvals
13
FDA:13
Drug Approvals
- Prev
- 1
- 2
- Next
Clinical Trials
No trials found
News
MSD and Cyprumed Forge $493 Million Deal to Advance Oral Peptide Therapeutics
MSD (Merck & Co.) has secured non-exclusive global rights to Cyprumed's oral peptide delivery platform, potentially transforming injectable peptide treatments into convenient tablet formulations.
UCB Launches Comprehensive Bimzelx Navigate Program to Enhance Patient Access and Support
UCB's Bimzelx Navigate program offers bridge access to therapy at $15 per dose for up to 2 years, addressing insurance coverage delays for commercially insured patients.